Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB3 over exp||prostate cancer||sensitive||Patritumab deruxtecan||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, Patritumab deruxtecan (U3-1402) inhibited growth of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture and in a patient-derived xenograft (PDX) model, but did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775).||34753775|